Iambic Therapeutics: chairperson William Rastetter received 200,920 shares

What happened

• William H. Rastetter, director and chairperson of the board, reported conversions of convertible preferred securities into a total of 200,920 shares of common stock on Oct 16, 2026.
• The filing shows acquired entries of 192,579 shares and 8,341 shares (price N/A) and disposed entries of 76,801 shares, 64,001 shares, 36,805 shares, 14,972 shares and 8,341 shares at $0.00 (derivative).

Key details

• Transaction date: Oct 16, 2026; reported on Form 4 filed Oct 19, 2026.
• Prices and values reported: acquired shares listed as N/A; disposed shares reported at $0.00.
• Shares owned after the transaction: not reported in this Form 4.
• Relevant footnotes from the filing: F1–F4 state each Series B, B-2, B-3 and B-4 convertible preferred share converted one-to-one into common stock immediately prior to the issuer's initial public offering and had no expiration date; F5 indicates some shares are held of record by the Rastetter Family Trust dated Sep 2, 2010, for which Dr. Rastetter is a trustee; F6 states the conversion price equaled 85% of the issuer's IPO price of $16.00 per share (reflecting a 15% discount), i.e., $13.60 per share.
• Filing timeliness: the Form 4 does not indicate a late filing.

Why it may matter

• These entries report conversions of convertible preferred securities into common stock rather than open-market purchases or sales.
• A filing does not show why the insider traded or why the company acted.